Genome-wide Association Study Identifies Two Susceptibility Loci for Osteosarcoma

Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. In order to better understand the genetic etiology of osteosarcoma, we performed a multi-stage genome-wide association study (GWAS) consisting of 941 cases and 3,291 cancer-free adult controls of European ancestry. Two loci achieved genome-wide significance: rs1906953 at 6p21.3, in the glutamate receptor metabotropic 4 [GRM4] gene (P = 8.1 ×10-9), and rs7591996 and rs10208273 in a gene desert on 2p25.2 (P = 1.0 ×10-8 and 2.9 ×10-7). These two susceptibility loci warrant further exploration to uncover the biological mechanisms underlying susceptibility to osteosarcoma

Genome-wide association study identifies two susceptibility loci for osteosarcoma

Osteosarcoma is the most common primary bone malignancy of adolescents and young adults. To better understand the genetic etiology of osteosarcoma, we performed a multistage genome-wide association study consisting of 941 individuals with osteosarcoma (cases) and 3,291 cancer-free adult controls of European ancestry. Two loci achieved genome-wide significance: a locus in the GRM4 gene at 6p21.3 (encoding glutamate receptor metabotropic 4; rs1906953; P = 8.1 × 10⁻⁹) and a locus in the gene desert at 2p25.2 (rs7591996 and rs10208273; P = 1.0 × 10⁻⁸ and 2.9 × 10⁻⁷, respectively). These two loci warrant further exploration to uncover the biological mechanisms underlying susceptibility to osteosarcoma

Turkey Urticaria Diagnosis and Treatment Guide based; Distribution of Chronic Urticaria Patients Treated in Our Clinic According to Step Therapy

Aim: Chronic urticaria is a condition that requires long-term treatment. In recent years, many countries have created their own guides to evaluate urticaria diagnosis and treatment approaches in an algorithm. In this study, we aimed to evaluate the distribution of patients with chronic urticaria treated in our clinic according to the treatment algorithm the "Turkey Urticaria Diagnosis and Treatment Guide" Material and Method: The files of the patients who applied to the Department of Dermatology and Venereal Diseases at Selcuk University and were followed up and treated with the diagnosis of chronic urticaria were investigated. Results: A total of 102 chronic urticaria patients without angioedema were included in the study. According to this guide, 17.6% of patients responded with standard dose antihistamine therapy, while the antihistamine dose given in 15.7% of patients was increased. The antihistamine treatment of 5.7% of patients was replaced by a different group of antihistamines at the same dose as the previous one. 52% of patients responded to omalizumab 300 mg / subcutaneous treatment every 28 days. However, 7.8% of the patients received omalizumab treatment every 14 days or cyclosporine treatment was required to be added to omalizumab treatment. Response to other treatments other than standard treatments was received in 1% of patients. Conclusion: We believe that our study will facilitate predicting the treatment responses of patients in clinical practice by shedding light on the distribution of chronic urticaria patients according to the treatment algorithm

Melatonin attenuates renal ischemia-reperfusion injury in nitric oxide synthase inhibited rats

Recent studies show that melatonin reduces the blood pressure (BP) and ischemia/ reperfusion (I/R)-induced damage. This study was designed to investigate the effects of melatonin on the renal I/R injury in rats given the nitric oxide synthase (NOS) inhibitor, N-omega-nitro-L-arginine methyl ester (L-NAME). After right nephrectomy, I/R was induced by occlusion of the left renal. vessels for 60 min, followed by 24h reperfusion. The administration of melatonin significantly attenuated BP in NOS-inhibited hypertensive rats. Malondialdehyde (MDA) levels, a stable metabolite of the free-radical-mediated lipid peroxidation cascade, were found to be significantly higher in the I/R group (3.48 +/- 0.2mg/l serum) than in the control group (2.69 +/- 0.2mg/l serum). L-NAME (40mgkg(-1) for 15 days)+I/R significantly increased the MDA levels compared to I/R alone. Melatonin administration to L-NAME rats significantly reduced the MDA values resulting from I/R. We also demonstrated that I/R, and especially L-NAME+I/R, lead to structural changes in the kidney and that melatonin attenuates these changes. These results suggest that metatonin reduces BP and I/R injury in NOS inhibited rats by L-NAME. (c) 2006 Elsevier GmbH. All. rights reserved